Additional Phase I studies involving allogenic CTLs expressing genetically modified T cells targeting IL13Rα2 (NCT01082926) and CAR modified CMV-specific cytotoxic lymphocytes (NCT01109095) indicate that this approach is clinically applicable, with minimal therapy related side effects and transient anti-glioma responses in a IL13Rα2-expressing GBM tumour cohort [32, 33]. This evidence concerns the gene IL13RA2 and neoplasm.